← BRIGHT MINDS BIOSCIENCES INC. (DRUG) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
BRIGHT MINDS BIOSCIENCES INC. (DRUG)
Pharmaceutical Preparations · market cap $577M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
5
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Bright Minds Biosciences Inc. is a small pharmaceutical company (26 employees, ~$623M market cap) with a pipeline centered on semaglutide-based and novel small-molecule assets across Type 2 Diabetes, obesity, and absence epilepsy. The company has two PDUFA dates in late 2026 and a Phase 3 readout expected imminently, making the next six months event-dense. Key structural concerns include elevated short interest (21%), a recent insider net sale of ~$9.8M, and disclosed elevated dilution risk with no financial details publicly available.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Drug: : 10 mg BGM0504 Administered SC | Phase 3 | Type 2 Diabetes Mellitus (T2DM) |
| BMB-101 | Phase 2 | Absence Epilepsy |
| BGM0504 | Phase 2 | Overweight or Obesity |
| BGM0504 Administered SC | Phase 2 | Type 2 Diabetes |
| Drug: 5 mg BGM0504 Administered SC | Phase 3 | Type 2 Diabetes Mellitus (T2DM) |
Price & technical context
3-month
-25.1%
6-month
-31.7%
12-month
-13.3%
52-wk range
$49.74–$95.99
vs 50-day MA
-28.8%
vs 200-day MA
-35.2%
Realized vol
63.7%
Max drawdown
-58.3%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DRUG (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.